{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:50:27Z","timestamp":1779893427177,"version":"3.53.1"},"reference-count":146,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Sickle cell disease (SCD) is a hemoglobinopathy characterized by hemolysis, vaso-occlusion, and systemic inflammation. Epidemiological studies identified an increased risk of leukemia, especially acute myeloid leukemia (AML), in individuals with SCD, whereas data regarding other tumors are conflicting. SCD-associated AMLs frequently display high-risk features with unfavorable karyotypes and a dismal prognosis. SCD is associated with multiple phenomena linked to carcinogenesis in other contexts, including chronic inflammation, oxidative stress, ineffective erythropoiesis, accelerated hematopoietic aging, impaired tumor immunosurveillance, and increased clonal hematopoiesis. The role and respective contribution of these disease-intrinsic mechanisms in SCD remain to be studied. Although therapies used in SCD could theoretically modulate the risk of malignancies, no data exist to support an increased or reduced risk associated with their use. The most notable exception is hematopoietic stem cell transplantation and, to a lesser extent, gene therapy, for which the conditioning and\/or procedure itself is known to increase the risk of leukemia. In sum, the effect of SCD on carcinogenesis is an emerging area of investigation with data supporting specificities in SCD-associated AML. Future research is required to determine the role of treatments to mitigate the increased risk and improve the outcome of SCD-associated AML.<\/jats:p>","DOI":"10.3390\/jcm14238509","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:20:29Z","timestamp":1765210829000},"page":"8509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["When Blood Disorders Meet Cancer: Uncovering the Oncogenic Landscape of Sickle Cell Disease"],"prefix":"10.3390","volume":"14","author":[{"given":"Elise","family":"Casadessus","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, 3175 Chemin de la C\u00f4te Sainte-Catherine, Montreal, QC H3T 1C5, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2110-5576","authenticated-orcid":false,"given":"Manon","family":"Saby","sequence":"additional","affiliation":[{"name":"CHU Sainte-Justine Azrieli Research Center, Montreal, QC H3T 1C5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-9234","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Fort\u00e9","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"Centre de Recherche du Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CRCHUM), Montreal, QC H2X 0A9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pastore","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, 3175 Chemin de la C\u00f4te Sainte-Catherine, Montreal, QC H3T 1C5, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"CHU Sainte-Justine Azrieli Research Center, Montreal, QC H3T 1C5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent-Philippe","family":"Lavall\u00e9e","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, 3175 Chemin de la C\u00f4te Sainte-Catherine, Montreal, QC H3T 1C5, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"CHU Sainte-Justine Azrieli Research Center, Montreal, QC H3T 1C5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-333X","authenticated-orcid":false,"given":"Thomas","family":"Pincez","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, CHU Sainte-Justine, 3175 Chemin de la C\u00f4te Sainte-Catherine, Montreal, QC H3T 1C5, Canada"},{"name":"Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, Montreal, QC H3T 1J4, Canada"},{"name":"CHU Sainte-Justine Azrieli Research Center, Montreal, QC H3T 1C5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOH.0000000000000642","article-title":"Ineffective erythropoiesis in sickle cell disease: New insights and future implications","volume":"28","author":"Godard","year":"2021","journal-title":"Curr. Opin. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1177\/15353702211068522","article-title":"Sickle cell disease as an accelerated aging syndrome","volume":"247","author":"Idris","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: A systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pathol.2016.10.002","article-title":"Sickle cell disease in the older adult","volume":"49","author":"Thein","year":"2017","journal-title":"Pathology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40266-023-01014-8","article-title":"Management of Older Adults with Sickle Cell Disease: Considerations for current and emerging therapies","volume":"40","author":"Oyedeji","year":"2023","journal-title":"Drugs Aging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/(SICI)1096-8652(199707)55:4<188::AID-AJH4>3.0.CO;2-O","article-title":"Cancer incidence rate and mortality rate in sickle cell disease patients at Howard University Hospital: 1986\u20131995","volume":"55","author":"Dawkins","year":"1997","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.10427","article-title":"Malignancy in patients with sickle cell disease","volume":"74","author":"Schultz","year":"2003","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0141076816651037","article-title":"Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study","volume":"109","author":"Seminog","year":"2016","journal-title":"J. R. Soc. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2017-05-783233","article-title":"Increased risk of leukemia among sickle cell disease patients in California","volume":"130","author":"Brunson","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2522967","DOI":"10.1080\/07853890.2025.2522967","article-title":"Risk of cancer in patients with thalassemia and sickle cell disease: A systematic review","volume":"57","author":"Merolle","year":"2025","journal-title":"Ann. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.34509","article-title":"Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021","volume":"129","author":"Origa","year":"2023","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/000992287201100313","article-title":"Frequency and prognosis of coexisting sickle cell disease and acute leukemia in children","volume":"11","author":"Jackson","year":"1972","journal-title":"Clin. Pediatr."},{"key":"ref_17","first-page":"453","article-title":"Sickle cell anemia with acute myeloid leukemia\u2013(a case report)","volume":"16","author":"Samal","year":"1979","journal-title":"Indian Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0002-9343(82)90189-9","article-title":"Left elbow pain and death in a young woman with sickle-cell anemia","volume":"73","author":"Deuel","year":"1982","journal-title":"Am. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-4608(86)90007-5","article-title":"9p- in a girl with acute lymphocytic leukemia and sickle cell disease","volume":"21","author":"Bigner","year":"1986","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ajh.2830210212","article-title":"Hematologic malignancy in sickle cell disease: Report of four cases and review of the literature","volume":"21","author":"Stricker","year":"1986","journal-title":"Am. J. Hematol."},{"key":"ref_22","first-page":"158","article-title":"Acute lymphoblastic leukaemia in a Nigerian adult with sickle cell anaemia","volume":"34","author":"Njoku","year":"1988","journal-title":"Cent. Afr. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.5858\/1999-123-0745-ALLISC","article-title":"Acute lymphoblastic leukemia in sickle cell disease","volume":"123","author":"Sotomayor","year":"1999","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/adc.81.5.437","article-title":"Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. French Study Group on Sickle Cell Disease","volume":"81","author":"Bernaudin","year":"1999","journal-title":"Arch. Dis. Child."},{"key":"ref_25","first-page":"415a","article-title":"Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia","volume":"94","author":"Rauch","year":"1999","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-133-11-200012050-00029","article-title":"Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea","volume":"133","author":"Wilson","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"ref_27","first-page":"1411","article-title":"Are we underestimating the leukemogenic risk of hydroxyurea","volume":"23","author":"Esan","year":"2002","journal-title":"Saudi Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-2141.2003.04614.x","article-title":"Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea Malignancies in sickle cell disease patients treated with hydroxyurea","volume":"123","author":"Ferster","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-155-10-201111150-00024","article-title":"Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia","volume":"155","author":"Taylor","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4137\/CMO.S8810","article-title":"Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia","volume":"6","author":"Baz","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23768","article-title":"Peripheral blood features of acute myeloid leukemia with myelodysplasia-related changes developing in a patient with sickle cell anemia","volume":"89","author":"Zemenides","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1002\/ajh.24010","article-title":"Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia","volume":"90","author":"Aumont","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.22159\/ajpcr.2018.v11i3.22790","article-title":"Incidence of hematological malignancies in sickle cell patients from an indian tertiary care teaching hospital","volume":"11","author":"Chauhan","year":"2018","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10428194.2017.1324158","article-title":"Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease","volume":"59","author":"Janakiram","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41379-019-0325-6","article-title":"Myeloid neoplasms in the setting of sickle cell disease: An intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature","volume":"32","author":"Li","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: A retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/15384047.2019.1647055","article-title":"Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient","volume":"20","author":"Regan","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.4314\/ahs.v20i3.36","article-title":"Acute leukemia in sickle cell disease patients in a tertiary health facility in Nigeria: A case series","volume":"20","author":"Aworanti","year":"2020","journal-title":"Afr. Health Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1159\/000508361","article-title":"Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea","volume":"13","author":"Yadav","year":"2020","journal-title":"Case Rep. Oncol."},{"key":"ref_40","first-page":"1185","article-title":"Baseline TP53 mutations in adults with SCD developing myeloid malignancy following hematopoietic cell transplantation","volume":"135","author":"Ghannam","year":"2020","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Chellapandian, D., and Nicholson, C.L. (2020). Haploidentical bone marrow transplantation in a patient with sickle cell disease and acute myeloid leukemia. Pediatr. Transpl., 24.","DOI":"10.1111\/petr.13641"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1182\/bloodadvances.2019001330","article-title":"Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease","volume":"4","author":"Hsieh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13256-021-03060-5","article-title":"Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia with e1a3 BCR-ABL1 transcript in a Nigerian with sickle cell anemia: A case report","volume":"15","author":"Ahmed","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease","volume":"386","author":"Goyal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Flevari, P., Voskaridou, E., Galact\u00e9ros, F., Cannas, G., Loko, G., Joseph, L., Bartolucci, P., Gellen-Dautremer, J., Bernit, E., and Charneau, C. (2022). Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review. Biomedicines, 10.","DOI":"10.3390\/biomedicines10123201"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s00277-023-05294-3","article-title":"Sickle cell disease and acute leukemia: One case report and an extensive review","volume":"102","author":"Cannas","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Bokhary, M., Turak, E., Ibrahim, R., Rashed, A., Abdelhadi, M., Ozturk, C., Sudha, S., Kaynar, L., and Fadel, E. (2025). Acute Promyelocytic Leukemia in a Patient With Sickle Cell Hemoglobin D Disease: A Case Report. Cureus, 17.","DOI":"10.7759\/cureus.87513"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1182\/blood-2023-187715","article-title":"Co-Diagnosis of Sickle Cell and Chronic Myelogenous Leukemia: Exploratory Analysis from a Nationally Representative Database","volume":"142","author":"Maiocco","year":"2023","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tomasik, J., and Basak, G.W. (2022). Inflammasomes-New Contributors to Blood Diseases. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158129"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3233\/CH-189012","article-title":"Inflammation in Sickle Cell Disease","volume":"68","author":"Conran","year":"2018","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1182\/blood.2021014894","article-title":"HbS promotes TLR4-mediated monocyte activation and proinflammatory cytokine production in sickle cell disease","volume":"140","author":"Allali","year":"2022","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.dnarep.2019.102673","article-title":"Inflammation-Induced DNA Damage, Mutations and Cancer","volume":"83","author":"Kay","year":"2019","journal-title":"DNA Repair"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1440-1681.2007.04639.x","article-title":"Sickle cell disease: Role of reactive oxygen and nitrogen metabolites","volume":"34","author":"Wood","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ajh.22012","article-title":"CURAMA Study Group Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management","volume":"86","author":"Nur","year":"2011","journal-title":"Am. J. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Pavitra, E., Acharya, R.K., Gupta, V.K., Verma, H.K., Kang, H., Lee, J.-H., Sahu, T., Bhaskar, L., Raju, G.S.R., and Huh, Y.S. (2024). Impacts of oxidative stress and anti-oxidants on the development, pathogenesis, and therapy of sickle cell disease: A comprehensive review. Biomed. Pharmacother., 176.","DOI":"10.1016\/j.biopha.2024.116849"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Antwi-Boasiako, C., B. Dankwah, G., Aryee, R., Hayfron-Benjamin, C., S. Donkor, E., and D. Campbell, A. (2019). Oxidative Profile of Patients with Sickle Cell Disease. Med. Sci., 7.","DOI":"10.3390\/medsci7020017"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12964-023-01398-5","article-title":"Interplay of oxidative stress, cellular communication and signaling pathways in cancer","volume":"22","author":"Iqbal","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12943-025-02375-x","article-title":"Oxidative stress in cancer: From tumor and microenvironment remodeling to therapeutic frontiers","volume":"24","author":"Liang","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10238-008-0153-3","article-title":"Sensitivity to cisplatin-induced mutations and elevated chromosomal aberrations in lymphocytes from sickle cell disease patients","volume":"8","author":"Alves","year":"2008","journal-title":"Clin. Exp. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature14131","article-title":"Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells","volume":"520","author":"Walter","year":"2015","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.3324\/haematol.2020.265462","article-title":"Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease","volume":"106","author":"Hoss","year":"2021","journal-title":"Haematologica"},{"key":"ref_63","first-page":"1150","article-title":"Reduced GATA1 levels are associated with ineffective erythropoiesis in sickle cell anemia","volume":"110","author":"Shangaris","year":"2025","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.seminhematol.2024.01.005","article-title":"Clonal hematopoiesis in children with predisposing conditions","volume":"61","author":"Attardi","year":"2024","journal-title":"Semin. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.stem.2018.10.013","article-title":"Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis","volume":"23","author":"Cai","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1182\/blood-2011-07-356006","article-title":"From stem cell to red cell: Regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications","volume":"118","author":"Hattangadi","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1182\/blood-2012-09-456079","article-title":"Quantitative analysis of murine terminal erythroid differentiation in vivo: Novel method to study normal and disordered erythropoiesis","volume":"121","author":"Liu","year":"2013","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"100585","DOI":"10.1016\/j.blre.2019.06.002","article-title":"Thalassemia and malignancy: An emerging concern?","volume":"37","author":"Hodroj","year":"2019","journal-title":"Blood Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"104711","DOI":"10.1016\/j.exphem.2025.104711","article-title":"How age affects human hematopoietic stem and progenitor cells and the strategies to mitigate aging","volume":"143","author":"Li","year":"2025","journal-title":"Exp. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hellmich, C., Moore, J.A., Bowles, K.M., and Rushworth, S.A. (2020). Bone Marrow Senescence and the Microenvironment of Hematological Malignancies. Front. Oncol., 10, Available online: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/10.3389\/fonc.2020.00230\/full.","DOI":"10.3389\/fonc.2020.00230"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2022.11.001","article-title":"Hallmarks of aging: An expanding universe","volume":"186","author":"Blasco","year":"2023","journal-title":"Cell"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00439-006-0144-y","article-title":"Genetic influence on human lifespan and longevity","volume":"119","author":"Iachine","year":"2006","journal-title":"Hum. Genet."},{"key":"ref_73","first-page":"E112","article-title":"Telomere attrition in sickle cell anemia","volume":"92","author":"Cecchini","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bjhh.2017.02.007","article-title":"Telomere length correlates with disease severity and inflammation in sickle cell disease","volume":"39","author":"Colella","year":"2017","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/bjh.15437","article-title":"Potential involvement of ubiquitin-proteasome system dysfunction associated with oxidative stress in the pathogenesis of sickle cell disease","volume":"182","author":"Warang","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/lipd.12027","article-title":"Decreased Serum Levels of Sphingomyelins and Ceramides in Sickle Cell Disease Patients","volume":"53","author":"Aslan","year":"2018","journal-title":"Lipids"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2023011188","article-title":"Characterizing epigenetic aging in an adult sickle cell disease cohort","volume":"8","author":"Hatch","year":"2024","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Blasco","year":"2013","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/blood.2022017933","article-title":"Hematopoietic stem cell aging and leukemia transformation","volume":"142","author":"Mistry","year":"2023","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjh.12950","article-title":"The spleen and sickle cell disease: The sick(led) spleen","volume":"166","author":"Brousse","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00268-017-4185-2","article-title":"Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes","volume":"42","author":"Rottenstreich","year":"2018","journal-title":"World J. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/j.1538-7836.2008.03024.x","article-title":"Delayed adverse vascular events after splenectomy in hereditary spherocytosis","volume":"6","author":"Schilling","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijsu.2015.10.011","article-title":"Splenectomy is associated with a higher risk for venous thromboembolism: A prospective cohort study","volume":"24","author":"Lee","year":"2015","journal-title":"Int. J. Surg."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1002\/ajh.26879","article-title":"Relevance of Howell-Jolly body counts for measuring spleen function in sickle cell disease","volume":"98","author":"Pourdieu","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2013.092460","article-title":"Long-term risks after splenectomy among 8,149 cancer-free American veterans: A cohort study with up to 27 years follow-up","volume":"99","author":"Kristinsson","year":"2014","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/bmm-2023-0086","article-title":"Altered T-cell profile in sickle cell disease","volume":"17","author":"Patel","year":"2023","journal-title":"Biomark. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2020.04.012","article-title":"Immune mechanisms involved in sickle cell disease pathogenesis: Current knowledge and perspectives","volume":"224","author":"Malmegrim","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ajh.23629","article-title":"Partial dysfunction of Treg activation in sickle cell disease","volume":"89","author":"Vingert","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.immuni.2025.04.020","article-title":"Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity","volume":"58","author":"Zhao","year":"2025","journal-title":"Immunity"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/bjh.16273","article-title":"Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention","volume":"188","author":"Dutta","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/ajh.25019","article-title":"Intestinal microbiome analysis revealed dysbiosis in sickle cell disease","volume":"93","author":"Lim","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s42255-025-01287-w","article-title":"The gut microbiome and cancer: From tumorigenesis to therapy","volume":"7","author":"Nobels","year":"2025","journal-title":"Nat. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Kandalai, S., Li, H., Zhang, N., Peng, H., and Zheng, Q. (2023). The human microbiome and cancer: A diagnostic and therapeutic perspective. Cancer Biol. Ther., 24.","DOI":"10.1080\/15384047.2023.2240084"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Todor, S.B., and Ichim, C. (2025). Microbiome Modulation in Pediatric Leukemia: Impact on Graft-Versus-Host Disease and Treatment Outcomes: A Narrative Review. Children, 12.","DOI":"10.3390\/children12020166"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2007.08.014","article-title":"Redox-dependent impairment of vascular function in sickle cell disease","volume":"43","author":"Aslan","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-17-3044","article-title":"New Insights from Studies of Clonal Hematopoiesis","volume":"24","author":"Gibson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_101","first-page":"1615","article-title":"Clonal hematopoiesis in the inherited bone marrow failure syndromes","volume":"136","author":"Tsai","year":"2020","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_105","first-page":"1590","article-title":"Clonal hematopoiesis: Mechanisms driving dominance of stem cell clones","volume":"136","author":"Challen","year":"2020","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.2021011121","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"138","author":"Pincez","year":"2021","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e156060","DOI":"10.1172\/JCI156060","article-title":"Clonal hematopoiesis in sickle cell disease","volume":"132","author":"Liggett","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2001.19.5.1405","article-title":"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis","volume":"19","author":"Christiansen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Cull","year":"2023","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Gondek, L.P., Sheehan, V.A., and Fitzhugh, C.D. (2022). Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113160"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/pr.2013.227","article-title":"Emerging science of hydroxyurea therapy for pediatric sickle cell disease","volume":"75","author":"Green","year":"2014","journal-title":"Pediatr. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.mrgentox.2012.08.003","article-title":"DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype","volume":"749","author":"Barbosa","year":"2012","journal-title":"Mutat. Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/em.22260","article-title":"Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity","volume":"60","author":"Pereira","year":"2019","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature04478","article-title":"Angiogenesis in life, disease and medicine","volume":"438","author":"Carmeliet","year":"2005","journal-title":"Nature"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"17360","DOI":"10.1073\/pnas.1109272108","article-title":"Hydroxyurea induces de novo copy number variants in human cells","volume":"108","author":"Arlt","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/em.22233","article-title":"Effects of hydroxyurea on CNV induction in the mouse germline","volume":"59","author":"Arlt","year":"2018","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"939","DOI":"10.7326\/0003-4819-148-12-200806170-00221","article-title":"Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease","volume":"148","author":"Lanzkron","year":"2008","journal-title":"Ann. Intern. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bjh.13093","article-title":"Hydroxycarbamide treatment in sickle cell disease: Estimates of possible leukaemia risk and of hospitalization survival benefit","volume":"167","author":"Castro","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/ajh.26286","article-title":"Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study","volume":"96","author":"Voskaridou","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Pincez, T., and Pastore, Y.D. (Int. J. Lab. Hematol., 2025). Molecular Testing in Sickle Cell Disease: From Newborn Screening to Transfusion Care, Int. J. Lab. Hematol., early view.","DOI":"10.1111\/ijlh.14513"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Galaris, D., Barbouti, A., and Pantopoulos, K. (2019). Iron homeostasis and oxidative stress: An intimate relationship. Biochim. Biophys. Acta (BBA)-Mol. Cell Res., 1866.","DOI":"10.1016\/j.bbamcr.2019.118535"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.cca.2019.11.029","article-title":"Iron overload: Effects on cellular biochemistry","volume":"504","author":"Sousa","year":"2020","journal-title":"Clinica Chimica Acta"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","article-title":"Iron homeostasis and ferroptosis in human diseases: Mechanisms and therapeutic prospects","volume":"9","author":"Ru","year":"2024","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Chai, X., Li, D., Cao, X., Zhang, Y., Mu, J., Lu, W., Xiao, X., Li, C., Meng, J., and Chen, J. (2015). ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem\/progenitor cells in mice. Sci. Rep., 5.","DOI":"10.1038\/srep10181"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12185-011-0988-3","article-title":"The effect of iron overload and chelation on erythroid differentiation","volume":"95","author":"Taoka","year":"2012","journal-title":"Int. J. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2011.08756.x","article-title":"Secondary cancers following allogeneic haematopoietic cell transplantation in adults","volume":"154","author":"Majhail","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","article-title":"Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning","volume":"117","author":"Majhail","year":"2011","journal-title":"Blood"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1532\/IJH97.03178","article-title":"Second malignant neoplasms following hematopoietic stem cell transplantation","volume":"79","author":"Friedman","year":"2004","journal-title":"Int. J. Hematol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41586-024-08128-y","article-title":"Clonal dynamics after allogeneic haematopoietic cell transplantation","volume":"635","author":"Wilk","year":"2024","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood.2021011488","article-title":"Leukemia after gene therapy for sickle cell disease: Insertional mutagenesis, busulfan, both, or neither","volume":"138","author":"Jones","year":"2021","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa2413361","article-title":"Tumor-Infiltrating Clonal Hematopoiesis","volume":"392","author":"Pich","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e789","DOI":"10.1016\/S2352-3026(25)00235-2","article-title":"Indicators of inequity in research and funding for sickle cell disease, cystic fibrosis and haemophilia: A descriptive comparative study","volume":"12","author":"Muzambi","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14656566.2024.2317336","article-title":"An update review of new therapies in sickle cell disease: The prospects for drug combinations","volume":"25","author":"Lugthart","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:29:44Z","timestamp":1765211384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/23\/8509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":146,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["jcm14238509"],"URL":"https:\/\/doi.org\/10.3390\/jcm14238509","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,30]]}}}